HSBC/CALL/MODERNA/280/0.1/20.06.24 | Real-time BOERSE MUENCHEN 07:00:21 07/06/2024 BST | ||
| 0.016 EUR | 0.00% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.016 | 0.00% |
| 06/06/24 | 0.016 | 0.00% |
| 05/06/24 | 0.016 | 0.00% |
| 04/06/24 | 0.016 | 0.00% |
| 03/06/24 | 0.016 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 07:00 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG4AK6 |
| ISIN | DE000HG4AK66 |
| Date issued | 23/06/2022 |
| Strike | 280 $ |
| Maturity | 20/06/2024 (14 Days) |
| Parity | 10 : 1 |
| Emission price | 1.81 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.73 € |
|---|---|
| Lowest since issue | 0.016 € |
| Spread | 0.03 € |
| Spread % | 96.77% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
154.7
USD
Average target price
142.8
USD
Spread / Average Target
-7.68%
- Stock Market
- Warrants
- Warrant
